Tenax Therapeutics (TENX) AI Stock Analysis

• Market Cap: $248.08M
• Dividend Yield: N/A
• Average Volume (3M): 449.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: N/A
• EPS Growth: 92.89%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 17,197,613
• 10 Day Avg. Volume: 476,821
• 30 Day Avg. Volume: 449,337
• PEG Ratio: -0.55
• Price to Book (P/B): 4.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.35
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $31.50
• Price Target Upside: 118.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.54
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $13.50 ▼(-6.38% Downside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is held back primarily by weak financial performance (pre-revenue, widening losses, and accelerating cash burn), which raises ongoing funding and dilution risk. Technicals are a meaningful positive with an established uptrend and positive momentum indicators, while valuation remains challenged due to negative earnings and no dividend yield data.

Positive Factors

Low leverage / $0 debt

A zero-debt capital structure materially lowers refinancing and interest obligations, preserving optionality for a clinical-stage biotech. That reduces short-term liquidity strain from interest payments and gives management flexibility to fund development via equity or partnerships without immediate debt pressure.

Negative Factors

Widening net losses

Sharply larger annual losses reflect accelerating development spend without commercial revenue, increasing the probability the company will need additional financing. Persistent, growing deficits reduce shareholder dilution visibility and constrain long-term operating flexibility absent clear financing plans.

Tenax Therapeutics Business Overview & Revenue Model

Company Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan...

Read more

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan...

How the Company Makes Money

null...

Tenax Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Mar 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-56.38M	-17.58M	-7.68M	-10.93M	-32.36M
Net Income	-52.60M	-17.60M	-7.71M	-11.05M	-32.47M
Balance Sheet
Total Assets	104.23M	96.69M	11.68M	3.40M	5.99M
Cash, Cash Equivalents and Short-Term Investments	97.56M	94.85M	9.79M	2.12M	5.58M
Total Debt	0.00	0.00	500.90K	807.89K	290.78K
Total Liabilities	7.16M	4.69M	3.59M	1.91M	1.75M
Stockholders Equity	97.07M	91.99M	8.10M	1.49M	4.24M
Cash Flow
Free Cash Flow	-35.80M	-14.81M	-5.90M	-12.02M	-10.86M
Operating Cash Flow	-35.80M	-14.81M	-5.90M	-12.01M	-10.86M
Investing Cash Flow	0.00	0.00	3.00K	-2.32K	452.61K
Financing Cash Flow	38.51M	99.87M	13.57M	8.55M	9.74M

Tenax Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TENX, the sentiment is Positive. The current price of 14.42 is below the 20-day moving average (MA) of 14.70, above the 50-day MA of 13.40, and above the 200-day MA of 9.51, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 50.86 is Neutral, neither overbought nor oversold. The STOCH value of 35.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TENX.

Tenax Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLMD	59 Neutral	$764.65M	-3.32	-170.83%	―	―	37.37%
TENX	53 Neutral	$248.08M	-9.09	-51.83%	―	―	92.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LGVN	50 Neutral	$26.99M	-0.39	-119.92%	―	-22.41%	78.88%
VYNE	48 Neutral	$20.33M	-0.94	-74.15%	―	6.29%	7.42%
TPST	46 Neutral	$29.41M	-0.45	-310.89%	―	―	49.43%
CLDI	40 Underperform	$2.79M	-0.52	―	―	―	87.42%

Tenax Therapeutics Corporate Events